People living with pancreatic cancer find themselves facing devastating odds – the five-year survival rate is in the single digits, according to the American Cancer Rate.
Pursuing treatment often means dealing with the side effects of systemic chemotherapy, including hair loss, fatigue and neuropathy. Shaun Bagai and his team at RenovoRx think that their catheter could help usher in a targeted treatment option for these patients.
The company’s RenovoCath dual-balloon infusion catheter is designed to localize the delivery of chemotherapy to a pancreatic tumor, eliminating the need for systemic chemotherapy and its associated side effects. In a 20-person first-in-human study, RenovoRx’s technology extended one patient’s survival to 31 months past their diagnosis, Bagai touted.
Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.
DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Early Registration is now open.